

Jorg Dietrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1576715/publications.pdf>

Version: 2024-02-01

129
papers

4,077
citations

136950

32
h-index

138484

58
g-index

130
all docs

130
docs citations

130
times ranked

6103
citing authors

#	ARTICLE	IF	CITATIONS
1	Central Nervous System Complications Among Oncology Patients. Hematology/Oncology Clinics of North America, 2022, 36, 217-236.	2.2	2
2	Improving Dâ€²â€²-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€²-receive/B₀â€²-him array coils at 3â€²%T. NMR in Biomedicine, 2022, 35, 2.8 e4621.		2
3	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology, 2022, 302, 410-418.	7.3	13
4	Antiepileptic drug therapy in brain tumor patients: a complex relationship. Neuro-Oncology Practice, 2022, 9, 83-84.	1.6	1
5	Factors associated with psychological distress in caregivers of patients with malignant gliomas. Supportive Care in Cancer, 2022, 30, 5811-5820.	2.2	3
6	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nature Communications, 2022, 13, 1325.	12.8	31
7	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 2567-2578.	7.0	20
8	In Vivo Absolute Metabolite Quantification Using a Multiplexed <scp>ERETICâ€²RX</scp> Array Coil for Wholeâ€²Brain <scp>MR</scp> Spectroscopic Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 121-133.	3.4	2
9	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
10	A controlled comparison of cerebral volume loss after brain irradiation with proton versus photon radiotherapy.. Journal of Clinical Oncology, 2022, 40, 2017-2017.	1.6	2
11	Phase 2 trial of baviximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2030-2030.	1.6	3
12	Strategies to Prevent or Remediate Cancer and Treatment-Related Aging. Journal of the National Cancer Institute, 2021, 113, 112-122.	6.3	57
13	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neuro-Oncology Practice, 2021, 8, 259-265.	1.6	3
14	MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab060.	0.7	5
15	Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy. European Journal of Cancer, 2021, 144, 178-181.	2.8	5
16	The best matrix for the brain: advances in secondary CNS lymphoma. Lancet Haematology, the, 2021, 8, e96-e97.	4.6	2
17	BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS. Neuro-Oncology Advances, 2021, 3, i5-i6.	0.7	0
18	A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood, 2021, 138, 382-386.	1.4	13

#	ARTICLE	IF	CITATIONS
19	Intracranial Foreign Body Granuloma Mimicking Brain Tumor Recurrence: A Case Series. <i>Oncologist</i> , 2021, 26, e893-e897.	3.7	3
20	Clinical Presentation and Management of SMART Syndrome. <i>Neurology</i> , 2021, 97, 118-120.	1.1	10
21	Chimeric Antigen Receptor T Cells for Glioblastoma. <i>Neurology</i> , 2021, 97, 218-230.	1.1	19
22	Myelopathies from Neoplasms. <i>Seminars in Neurology</i> , 2021, 41, 291-302.	1.4	0
23	Assessment and Management of Cognitive Symptoms in Patients With Brain Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e90-e99.	3.8	11
24	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
25	Reliability and validity of a novel cognitive self-assessment tool for patients with cancer. <i>Neuro-Oncology Practice</i> , 2021, 8, 691-698.	1.6	5
26	Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers. <i>Scientific Reports</i> , 2021, 11, 20045.	3.3	1
27	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	12.8	35
28	NCOG-48. LONGITUDINAL ASSESSMENT OF SUBJECTIVE COGNITIVE FUNCTION IN A BRAIN TUMOR SAMPLE: IMPROVED CORRESPONDENCE WITH NEUROPSYCHOLOGICAL PERFORMANCE OVER TIME. <i>Neuro-Oncology</i> , 2021, 23, vi162-vi162.	1.2	0
29	BIOM-09. MYO-INOSITOL LEVELS ON MR SPECTROSCOPY CAN PREDICT FAILURE OF ANTI-ANGIOGENIC TREATMENT IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi12.	1.2	0
30	Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma. <i>Blood</i> , 2021, 138, 258-258.	1.4	3
31	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	1.2	0
32	TAMI-29. MR SPECTROSCOPY MEASURES OF LAC/NAA AND NAA/CHO DIFFERENTIATE SURVIVORSHIP IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH ANTI-ANGIOGENIC THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi204-vi204.	1.2	0
33	NCOG-20. LONGITUDINAL ASSESSMENT OF SUBJECTIVE COGNITIVE FUNCTION IN ADULTS WITH LOW GRADE GLIOMA TREATED WITH PROTON RADIATION THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi156-vi156.	1.2	0
34	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49.	1.2	0
35	MRI findings in trigeminal neuropathy: bilateral Meckel's cave lesions. <i>Acta Neurologica Belgica</i> , 2020, 120, 171-173.	1.1	0
36	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	7.0	48

#	ARTICLE	IF	CITATIONS
37	Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. <i>Cancer Medicine</i> , 2020, 9, 3-11.	2.8	28
38	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. <i>Radiology</i> , 2020, 294, 589-597.	7.3	18
39	Central nervous system injury from novel cancer immunotherapies. <i>Current Opinion in Neurology</i> , 2020, 33, 723-735.	3.6	9
40	Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2020, 149, 153-159.	2.9	16
41	Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II. <i>Scientific Reports</i> , 2020, 10, 19758.	3.3	11
42	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2020, 150, 165-213.	2.9	6
43	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa157.	0.7	8
44	Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. <i>BMJ Neurology Open</i> , 2020, 2, e000054.	1.6	18
45	An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7T. <i>Scientific Reports</i> , 2020, 10, 15029.	3.3	12
46	Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. <i>Neuro-Oncology Practice</i> , 2020, 7, 490-497.	1.6	16
47	Ipilimumab: an investigational immunotherapy for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1187-1193.	4.1	16
48	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
49	Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis. <i>Oncologist</i> , 2020, 25, e1221-e1232.	3.7	23
50	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. <i>Oncologist</i> , 2020, 25, 747-e1273.	3.7	9
51	Primary dural lymphomas: Clinical presentation, management, and outcome. <i>Cancer</i> , 2020, 126, 2811-2820.	4.1	24
52	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa031.	0.7	8
53	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
54	Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2568-2568.	1.6	3

#	ARTICLE	IF	CITATIONS
55	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.. Journal of Clinical Oncology, 2020, 38, 2546-2546.	1.6	0
56	BIOM-15. SUBVENTRICULAR ZONE INVOLVEMENT IS ASSOCIATED WITH WORSE OUTCOME IN GLIOMA WHO GRADE II INDEPENDENT OF MOLECULAR MARKERS. Neuro-Oncology, 2020, 22, ii4-ii5.	1.2	1
57	NCOG-70. RELIABILITY AND VALIDITY OF A NEW SELF-REPORT INDEX OF COGNITIVE CONCERNS IN BRAIN TUMOR PATIENTS. Neuro-Oncology, 2020, 22, ii145-ii145.	1.2	0
58	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. Neuro-Oncology, 2020, 22, ii13-ii13.	1.2	0
59	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019, 134, 860-866.	1.4	178
60	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer, 2019, 125, 3692-3698.	4.1	42
61	Cognitive Performance and Psychological Distress in Breast Cancer Patients at Disease Onset. Frontiers in Psychology, 2019, 10, 2584.	2.1	20
62	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Medicine, 2019, 8, 5988-5994.	2.8	23
63	Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncology, The, 2019, 20, e92-e102.	10.7	68
64	Assessment and management of cognitive changes in patients with cancer. Cancer, 2019, 125, 1958-1962.	4.1	5
65	Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 133-145.	3.8	65
66	Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro-Oncology, 2019, 21, 1118-1130.	1.2	37
67	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood, 2019, 133, 2212-2221.	1.4	207
68	EXTH-39. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY. Neuro-Oncology, 2019, 21, vi90-vi90.	1.2	0
69	QOLP-38. PATIENT REPORTED OUTCOMES IN GLIOMA: THE ROLE OF IDH MUTATION ON QUALITY OF LIFE AND MOOD. Neuro-Oncology, 2019, 21, vi206-vi206.	1.2	0
70	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Advances, 2019, 3, 375-383.	5.2	77
71	Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES). Journal of Cancer Research and Clinical Oncology, 2019, 145, 1917-1918.	2.5	7
72	Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. Journal of Neuro-Oncology, 2019, 142, 69-77.	2.9	39

#	ARTICLE	IF	CITATIONS
73	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. <i>Oncologist</i> , 2019, 24, 402-413.	3.7	3
74	Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. <i>Journal of Neurosurgery</i> , 2019, 130, 804-811.	1.6	114
75	Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2032-2032.	1.6	33
76	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	12.8	106
77	Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. <i>Neuro-Oncology</i> , 2018, 20, 289-291.	1.2	12
78	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. <i>Neuro-Oncology Practice</i> , 2018, 5, 64-68.	1.6	10
79	ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB,) Tj ETQq1 1 0.784314 rjB <i>Neuro-Oncology</i> , 2018, 20, vi10-vi10.	1.2	6
80	NCOG-04. EFFECTS OF PROTON RADIATION ON BRAIN STRUCTURE AND FUNCTION IN LOW GRADE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi173-vi173.	1.2	1
81	NCMP-22. TREATMENT-RELATED ADVERSE EFFECTS IN PATIENTS WITH MALIGNANT GLIOMA: ESTABLISHMENT OF KEY FEATURES FOR PSEUDOPROGRESSION AND TREATMENT-INDUCED NECROSIS.. <i>Neuro-Oncology</i> , 2018, 20, vi198-vi198.	1.2	1
82	HOUT-15. CIRCULATING BLOOD CELL COUNTS AS POTENTIAL BIOMARKERS OF OUTCOMES IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, vi116-vi116.	1.2	0
83	NCMP-17. EVOLUTION OF CEREBRAL MICROBLEEDS AFTER PROTON IRRADIATION IN LOW-GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi197-vi197.	1.2	1
84	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi14.	1.2	6
85	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi191.	1.2	0
86	EEG findings in CAR T-cell therapy-related encephalopathy. <i>Neurology</i> , 2018, 91, 227-229.	1.1	37
87	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2032-2032.	1.6	2
88	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14041-e14041.	1.6	1
89	Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. <i>Neurology</i> , 2017, 88, 789-796.	1.1	49
90	Role of ketogenic metabolic therapy in malignant glioma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 41-58.	4.4	67

#	ARTICLE	IF	CITATIONS
91	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	10.7	535
92	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. <i>Npj Precision Oncology</i> , 2017, 1, .	5.4	16
93	Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. <i>Journal of Neurosurgery</i> , 2017, 127, 132-138.	1.6	25
94	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	2.9	69
95	Neuroimaging of Brain Tumors: Pseudoprogression, Pseudoresponse, and Delayed Effects of Chemotherapy and Radiation. <i>Seminars in Neurology</i> , 2017, 37, 589-596.	1.4	19
96	Bone marrow drives central nervous system regeneration after radiation injury. <i>Journal of Clinical Investigation</i> , 2017, 128, 281-293.	8.2	36
97	Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2005-2005.	1.6	2
98	Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2042-2042.	1.6	44
99	A 34-Year-Old Male with An Intracranial Mass. <i>Brain Pathology</i> , 2016, 26, 289-290.	4.1	1
100	Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 505-514.	2.9	42
101	Perspectives on investigational drugs and immunotherapies for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1007-1009.	4.1	2
102	Engraftment of enteric neural progenitor cells into the injured adult brain. <i>BMC Neuroscience</i> , 2016, 17, 5.	1.9	13
103	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	7.0	127
104	Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2080-TPS2080.	1.6	4
105	A 20-Year-Old Man With Back Pain and Lower Extremity Weakness. <i>JAMA Neurology</i> , 2015, 72, 363.	9.0	1
106	MPTH-17CLINICAL AND MOLECULAR CHARACTERIZATION OF LONG-TERM GLIOBLASTOMA SURVIVORS. <i>Neuro-Oncology</i> , 2015, 17, v141.4-v142.	1.2	0
107	NTCT-03CEREBRAL MICROBLEEDS AFTER WHOLE BRAIN RADIATION THERAPY IN MEDULLOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v172.3-v172.	1.2	0
108	Remote acute demyelination after focal proton radiation therapy for optic nerve meningioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1367-1369.	1.5	4

#	ARTICLE	IF	CITATIONS
109	Standard chemoradiation for glioblastoma results in progressive brain volume loss. <i>Neurology</i> , 2015, 85, 683-691.	1.1	70
110	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2025-2025.	1.6	1
111	Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2077-TPS2077.	1.6	2
112	Magnetic Resonance Imaging Observations in Primary Central Nervous System Lymphoma. <i>JAMA Neurology</i> , 2014, 71, 918.	9.0	4
113	Neural correlates of chemotherapy-related cognitive impairment. <i>Cortex</i> , 2014, 54, 33-50.	2.4	104
114	Imaging of Cancer Therapyâ€“Induced Central Nervous System Toxicity. <i>Neurologic Clinics</i> , 2014, 32, 147-157.	1.8	15
115	Challenges in research on the neural basis of â€œchemobrainâ€œ. <i>Translational Neuroscience</i> , 2014, 5, .	1.4	3
116	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2053-2053.	1.6	1
117	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2104-TPS2104.	1.6	2
118	Corticosteroids in brain cancer patients: benefits and pitfalls. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 233-242.	3.1	263
119	Glioma stem cell signaling: therapeutic opportunities and challenges. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 709-722.	2.4	34
120	Chemotherapy Associated Central Nervous System Damage. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 77-85.	1.6	36
121	Effect of Cancer Treatment on Neural Stem and Progenitor Cells. <i>Cancer Treatment and Research</i> , 2009, 150, 81-95.	0.5	6
122	Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1549-1557.	4.1	50
123	Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 393-404.	4.3	47
124	Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. <i>Oncologist</i> , 2008, 13, 1285-1295.	3.7	297
125	Emerging antiangiogenic treatments for gliomas â€“ efficacy and safety issues. <i>Current Opinion in Neurology</i> , 2008, 21, 736-744.	3.6	46
126	Metastatic primary peritoneal carcinoma presenting as tension hydrothorax. <i>Lancet Oncology</i> , The, 2006, 7, 784.	10.7	1

#	ARTICLE	IF	CITATIONS
127	Role of Endogenous Neural Stem Cells in Neurological Disease and Brain Repair. , 2006, 557, 191-220.		37
128	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.7	2
129	Magnetic Resonance Spectroscopic Imaging for Detecting Metabolic Changes in Glioblastoma After Anti-angiogenic Therapy-A Systematic Literature Review. Neuro-Oncology Advances, 0, , .	0.7	0